Show Me The Money: After An 800%+ Gain, PRAX Enters A High-Stakes Stretch
· rttnews.com
With four late-stage assets, three FDA Breakthrough Therapy Designations, and two upcoming PDUFA decisions, Praxis Precision Medicines (PRAX), a CNS precision neuroscience biopharmaceutical company, is entering a defining chapter.
With four late-stage assets, three FDA Breakthrough Therapy Designations, and two upcoming PDUFA decisions, Praxis Precision Medicines (PRAX), a CNS precision n...